Medical Oncology

Prof. Dr. Erkan Doğan

Doctor and researcher Medicana Ataköy İstanbul

Open institution page

Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest stated by the doctor on the institution profile. Source: medicana.com.tr.

Meme Kanseri
Gastrointestinal Kanserler
Akciğer Kanseri
Karaciğer Kanseri
Nadir Görülen Kanserler

Education and experience

From source

Experience

1999-2004Taksim Eğitim ve Araştırma Hastanesi İç Hastalıkları Kliniğimedicana.com.tr
2004-2007Ağrı Patnos Devlet Hastanesi İç Hastalıkları Kliniğimedicana.com.tr
2007-2008Van Yüzüncü Yıl Üniversitesi Tıp Fakültesimedicana.com.tr
2008-2011Hacettepe Üniversitesi Tıp Fakültesimedicana.com.tr
2011-2013Van Eğitim ve Araştırma Hastanesimedicana.com.tr
2013-2017Van Yüzüncü Yıl Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Kliniğimedicana.com.tr
2017-2021İstanbul Yeni Yüzyıl Üniversitesi Gaziosmanpaşa Hastanesimedicana.com.tr
2021-2022Medical Park Bahçelievler Hastanesimedicana.com.tr
2022-2026Memorial Bahçelievler Hastanesimedicana.com.tr
2026-HalenMedicana Ataköy Hastanesimedicana.com.tr

Education

1998Marmara Üniversitesi Tıp Fakültesimedicana.com.tr
2011Hacettepe Üniversitesi Tıp Fakültesimedicana.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

SpecialtyMedical Oncologymedicana.com.trFrom source
Department name at the sourceMedikal Onkolojimedicana.com.trFrom source
InstitutionMedicana Ataköymedicana.com.trFrom source
Publications49 publicationsmedicana.com.tr profile pageFrom source
Last synchronised7 November 2026 03:25https://www.medicana.com.tr/hekim-detay/25441/erkan-doganmedicana.com.tr

Scientific work

Publications

49 publications

Adem Yokuş, Harun Arslan, Zülküf Akdemir, İbrahim Akbudak, Necat Almalı, Çetin Kotan, Erkan Doğan. Measurement of Postoperative Liver Volume Changes In Patients With Gastric Cancer By Computed Tomography. East J Med 28(2):206-210, 2023. DOI:10.5505/ejm.2023.12129

Source: medicana.com.tr profile page
Aycan A, Celik S, Kuyumcu F, Akyol ME, Arslan M, Dogan E, Arslan H. Spinal Metastasis of Unknown Primary Accompanied by Neurologic Deficit or Vertebral Instability. World Neurosurg. 2018 Jan;109:e33-e42. doi:10.1016/j.wneu.2017.09.099

Source: medicana.com.tr profile page
Arslan H, Fatih Özbay M, Çallı İ, Doğan E, Çelik S, Batur A, Bora A, Yavuz A, Bulut MD, Özgökçe M, Çetin Kotan M. Contribution of diffusion weighted MRI to diagnosis and staging in gastric tumors and comparison with multi-detector computed tomography. Radiol Oncol. 2017;51(1):23-29

Source: medicana.com.tr profile page
Sunnetcioglu A, Arısoy A, Demir Y, Ekin S, Dogan E. Associations between the standardized uptake value of 18F-FDG PET/CT and demographic, clinical, pathological, radiological factors in lung cancer. Int J Clin Exp Med. 2015;8(9):15794-800

Source: medicana.com.tr profile page
Turan N, Benekli M, Unal OU, Unek İT, Tastekin D ve ark. Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. Chin J Cancer Res. 2015;27(4):408-16

Source: medicana.com.tr profile page
Can A, Dogan E, Bayoglu IV ve ark. Multicenter epidemiologic study on hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev. 2014;15(6):2923-7

Source: medicana.com.tr profile page
Turan N, Benekli M, Dane F ve ark. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. Thorac Cancer. 2014;5(5):398-404

Source: medicana.com.tr profile page
Koca D, Dogan E, Yardim H ve ark. A modified DCF regimen as primary treatment for patients with metastatic gastric cancer. J BUON. 2013;18(2):377-84

Source: medicana.com.tr profile page
Dogan E, Yorgun H, Petekkaya I ve ark. Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: A single center experience. Med Oncol. 2012

Source: medicana.com.tr profile page
Dogan E, Yalcin S, Koca D, Olmez A. Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev. 2012;13:2985-90

Source: medicana.com.tr profile page

View all 49 publications

Other doctors in the same specialty

Memberships and more

European Society of Medical Oncology ESMO
Türk Tıbbi Onkoloji Derneği TTOD
Talasemi Dayanışma Derneği

Özellikli İşlemler (4)

Hedefe Yönelik Tedaviler
İmmünoterapiler
Kemoterapi
Hormonoterapiler

7.4. Uluslararası Dergilerde Yayımlanan Abstraktlar (2)

1. Sarici F, Aksoy S, Dizdar O, Dede D, Arslan C, Dogan E, Ozkan C, Cinel M, Yaman S, Kizilarslan C, Ozisik Y, Altundag K. The frequency and determinants of metabolic syndrome in patients with operable stage I-III breast cancer. 7th Metabolic Syndrome Symposium, Antalya, Turkey, 29 April-2 May 2010. Obesity Reviews. 2010;11:482. Abstract no 35, Ref no 72. SCIE
2. Kizilarslanoglu C, Aksoy S, Dizdar O, Dede D, Arslan C, Dogan E, Ozisik Y, Altundag K. Prognostic significance of body mass index in breast cancer patients. 7th Metabolic Syndrome Symposium, Antalya, Turkey, 29 April-2 May 2010. Obesity Reviews. 2010;11:483. Abstract no 36, Ref no 73. SCIE

14. Yer Aldığı Klinik Araştırmalar (8)

1. Comparative analysis of patient satisfaction between public hospitals and private hospital outpatient clinics. Marmara University Department of Public Health, 1998. Advisor Prof. Dr. Osman Hayran. Unpublished Research Report
2. Coinvestigator in the international INVEST study
3. Coinvestigator in the international Cariatide study
4. Coinvestigator in the international CA163-140 study. Phase II Combination of Trastuzumab and Ixabepilone versus Trastuzumab and Docetaxel in Patients with Advanced and or Metastatic Breast Cancer
5. Coinvestigator in the international ATHENA study
6. Subinvestigator in the national ERADA study
7. Tide 13-14 Observational Phase IV Study. Principal Investigator
8. A Phase 3 Randomized Double Blind Place Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Adenocarcinoma. NCT0254504. Ongoing

Source: medicana.com.tr

Ask Doctoria AI

Coming soon

In preparation for doctors, institutions and research teams. Examples of questions you will be able to ask:

Find the doctors with the most publications in Medical Oncology Find the researchers scientifically closest to this profile Find researchers for a multicentre study

Let’s improve this profile together

Every change is stored with its source, contributor and date.

Suggest a correction Add a publication Correct the institution Add a specialty Merge a duplicate record Claim profile

Last change: Profil medicana.com.tr sitesinden içe aktarıldı Source: https://www.medicana.com.tr/hekim-detay/25441/erkan-dogan
Contributor: Doctoria bot
Date: 7 November 2026 03:25